翻译后修改区分了大脑粉样蛋白血管病变和阿尔茨海默病中的粉样蛋白β异型
Srinivas Koutarapu1, Kaleigh F Roberts1, Reid A Coyle2,3
1Department of Pathology & Immunology, Division of Neuropathology, Washington University School of Medicine, St. Louis, Missouri, USA.
Journal of neurochemistry
|December 29, 2025
概括
大脑粉样蛋白血管病变 (CAA) 和阿尔茨海默病 (AD) 涉及粉样蛋白-β (Aβ) 沉积,但在Aβ修饰方面有所不同. 与AD斑块不同的是,CAA具有完整的N端和更短的C端.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 病理学 病理学 病理学
背景情况:
- 大脑粉样蛋白血管病变 (CAA) 和阿尔茨海默病 (AD) 分享粉样蛋白β (Aβ) 沉积,但表现出不同的病理特征.
- 了解CAA和AD之间的Aβ聚合和翻译后修饰 (PTM) 的分子差异对于向治疗至关重要.
研究的目的:
- 在阿尔茨海默氏病 (AD) 中研究和比较脑粉样血管病变 (CAA) 和副细胞质斑块之间的Aβ异型组成和N终端PTM.
- 探索CAA的严重程度如何影响Aβ PTM和异型形状.
主要方法:
- 使用Lys-N酶性消化与定量质谱相结合,以分析Aβ异型和N终端PTM (酸异体化,铁酸盐形成).
- 分析了不同程度的CAA严重程度的Aβ配置文件,并将它们与AD中帕伦基马斑块的Aβ进行了比较.
主要成果:
- 中度至重度的CAA主要具有完整的N端Aβ (Aβ1-x,~95%) 与最小的N截断物种,与AD帕伦基马斑块中的多种N端修饰形成鲜明对比.
- 增加的CAA严重程度与从较长的 (Aβ41-43) 转向较短的C端Aβ异型 (Aβ37-40) 的转变相关.
- 在中度和严重的CAA中,在Asp1和Asp7观察到最小的酸异构.
结论:
- 显而易见的Aβ聚合机制可能是CAA和AD帕伦基马斑块的基础,N-终端修饰和C-终端异型组成的差异证明了这一点.
- 在CAA中完整的,未经修改的N端可能是由于它被纳入原纤维结构的结果,与与斑块相关的Aβ相比,使其更难以获得PTM.
- 这些生化区别可能会为早期CAA检测的新生物标志物的开发提供信息,以及针对血管与辅酶Aβ病理的向治疗方法.
关键词:
阿尔茨海默病的疾病阿尔茨海默病的疾病.粉样蛋白-βββββββββββββββββββββββββββββββββββββββββββββββββββββββββββββ大脑粉样性血管病变 - 大脑粉样性血管病变质谱测量质谱测量质谱测量质谱测量质量测量质谱测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量质量测量帕伦奇玛斑块是一种表质斑块.更多相关视频
07:28Full- versus Sub-Regional Quantification of Amyloid-Beta Load on Mouse Brain Sections
Published on: May 19, 2022
4.5K
10:51Consensus Brain-derived Protein, Extraction Protocol for the Study of Human and Murine Brain Proteome Using Both 2D-DIGE and Mini 2DE Immunoblotting
Published on: April 10, 2014
16.6K
相关概念视频
Amyloid Fibrils
11.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
11.5K
Amyloid Fibrils
6.2K
6.2K
Alzheimer's Disease: Overview
1.5K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.5K
